Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs PROSTASCINT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
FDA-approved: Diagnostic imaging in patients with biopsy-proven prostate cancer who are at high risk for pelvic lymph node metastases or with rising PSA after local therapy,Off-label: None well-established
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
5 m Ci (185 MBq) intravenously over 5 minutes, single dose.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Capromab pendetide is a monoclonal antibody fragment; metabolism is via catabolism to amino acids and small peptides. The indium-111 label is not metabolized and decays physically.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
~90% (binding to plasma proteins, likely immunoglobulins and albumin)
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
5.5 L (not weight-adjusted; approximates intravascular space with slow distribution to extravascular tumor sites)
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
IV: 100% (not administered via other routes)
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No specific dose adjustment recommended; caution in severe renal impairment (GFR <30 m L/min) due to potential radiation clearance delay.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No specific adjustment for Child-Pugh class; caution in severe hepatic impairment due to altered clearance.
Not indicated for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established; not recommended for pediatric patients.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
No specific dose adjustment; follow standard adult dosing with consideration of renal function.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Not applicable.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Risk of hypersensitivity reactions, including anaphylaxis,Use of murine antibodies may cause human anti-mouse antibody (HAMA) response, potentially affecting subsequent murine antibody-based diagnostics or therapeutics,Radiation exposure from indium-111; risk of secondary malignancies,Limited data in patients with renal impairment
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Hypersensitivity to capromab pendetide, indium-111, or any component of the formulation,Pregnancy: potential fetal harm from radiation
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
No known food interactions. Maintain adequate hydration; no dietary restrictions required.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not available. The radiopharmaceutical component emits radiation; fetal radiation exposure may increase the risk of congenital anomalies and childhood malignancies. Use in pregnant women is contraindicated unless potential benefit outweighs risks. First trimester exposure poses highest risk of teratogenesis; second and third trimester exposure may increase risk of childhood cancer.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
Indium-111 is a radioactive isotope with a physical half-life of 2.8 days. Radioactive iodine may concentrate in breast milk. It is recommended to discontinue breastfeeding after administration. No M/P ratio available. To reduce radiation exposure to the infant, breastfeeding should be interrupted for a period based on the decay of indium-111 (typically at least 10 half-lives, i.e., 28 days). Pump and discard milk during this time.
Not applicable; contraindicated in pregnancy.
PROSTASCINT is contraindicated in pregnancy unless clearly needed. No pharmacokinetic data in pregnancy. Dose adjustment is not recommended as use should be avoided; if necessary, the minimum diagnostic activity should be used. Standard adult dose: 5 m Ci (0.5 mg antibody) intravenous. No adjustment for pregnancy-related pharmacokinetic changes due to lack of data.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Prostascint (capromab pendetide) is a radiolabeled monoclonal antibody used for imaging prostate-specific membrane antigen (PSMA) in patients with prostate cancer. For optimal imaging, allow 72 hours post-injection for clearance of unbound antibody. Use with caution in patients with known murine protein allergy; pre-medicate with antihistamines if prior reaction. False-positive scans may occur in benign prostatic hyperplasia or inflammation. Ensure adequate hydration to promote renal excretion of the radiopharmaceutical.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
This drug is a radioactive imaging agent that helps detect the spread of prostate cancer.,You will receive a single intravenous injection before your scan.,Drink plenty of water after the injection to help clear the radioactive material from your body.,Avoid close contact with pregnant women and young children for 24 hours after the scan.,Inform your doctor if you have had allergic reactions to mouse proteins or previous monoclonal antibody therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs PROSTASCINT, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. PROSTASCINT is a Radiopharmaceutical Diagnostic Agent that works by PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and PROSTASCINT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of PROSTASCINT is: 5 m Ci (185 MBq) intravenously over 5 minutes, single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and PROSTASCINT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. PROSTASCINT is classified as Category C. PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.